Drug Type Small molecule drug |
Synonyms XS 04 |
Target |
Action inhibitors |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors), IRAK4 inhibitors(Interleukin-1 receptor-associated kinase 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Myeloid Leukemia | Phase 1 | China | 30 Dec 2024 | |
Chronic Lymphocytic Leukemia | Phase 1 | China | 30 Dec 2024 | |
Myeloid Tumor | Phase 1 | China | 30 Dec 2024 | |
Small Lymphocytic Lymphoma | Phase 1 | China | 30 Dec 2024 | |
Diffuse Large B-Cell Lymphoma | Preclinical | China | 17 Apr 2023 |